AARP Study/VIDEO: Drugmaker Tactics to Forestall Generic Drug Availability
A new AARP Public Policy Institute “Rx Price Watch” case study released today sheds light on how drugmaker’s tactics to prevent or delay generic competition have intensified. See link for PDF of report below.
According to the AARP press release on PR Newswire:
The report breaks down the unusually aggressive strategy reportedly undertaken by Lipitor’s manufacturer (Pfizer) before and after the drug’s patent expired and discusses how the effort could become a model for other brand name drug manufacturers facing generic competition, ultimately increasing costs for consumers and publicly-funded programs like Medicare and Medicaid.
A Fierce Pharma article reviewing the report says “The AARP report itself is a pretty good playbook for drugmakers facing a patent loss.”